Company Profile

Lloyd Olson MD LLC
Profile last edited on: 8/2/2021      CAGE: 6HQ39      UEI: FC1DH6VNMQG6

Business Identifier: Redefinintion of a life-saving medical equipment for use in/out of hospital
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1615 North Cascade Avenue
Colorado Springs, CO 80907
   (719) 310-9530
Location: Single
Congr. District: 05
County: El Paso

Public Profile

Involving what seems to be a husband and wife team, the firm is addressing an issue of major concern: death from opioids usage primarily due to respiratory arrest. Noting that hypoxemia - low blood oxygen - typically precedes respiratory arrest and that timely detection and correction of hypoxemia can saves lives, the firm offers the he Oxalert EPO - a wearable device designed automatically to restore breathing and reverse hypoxemia without human intervention. Indicating the FDA as having recognized the frm's initial proposed Indication for Use in hospitalized post- operative patients receiving opioids, the team is working on feasibility both for in-hospital and at home, by patients at home using opioids. Prove feasibility of the Oxalert arousal device for restoring breathing and reversing hypoxemia in post-operative patients receiving opioids. AIM2) Determine statistical scalability needs for future Phase II study. AIM3) Evaluate patient tolerance, nurse feedbacl and human factors/usability. AIM4) Compare the extent of nocturnal oxygen desatuations in home-use before and after surgery, with and without Oxalert interventions. Summary: Breakthrough Device status should facilitate FDA approval for the Oxalert EPO. Devices with a favorable Risk:Benefit ratio under the Twenty-First Cures Act qualify for less FDA emphasis on lengthy pre-market studies as opposed to post-market data in order to expedite patient access. We hope to find the shortest path to getting this device to all who might benefit.Project Narrative The Oxalert EPO (Enhanced Pulse Oximeter) is a FDA-designated Breakthrough Device: andquot;an innovation that provides for more effective diagnosis and treatment of life-threatening conditions that offers significant advantages over any approved or cleared alternatives, the availability of which is in the best interests of patients.andquot;24 This wearable device uses continuous pulse oximetry, audible and tactile stimuli to arouse patients with respiratory depression to breathe and correct hypoxemia. Patient harm from respiratory arrest, myocardial ischemia and death from opioid overdose are likely preventable by arousing patients to reverse declining oxygenation at an early stage. The Oxalert is a non-invasive, automatic closed-loop apnea and hypoxemia prevention device, not dependent on human intervention, and more effective than continuous 1:1 nursing care.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $349,336
Project Title: Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death

Key People / Management

  Elizabeth Olson

  Lloud Olson

Company News

There are no news available.